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Introduction
The optimal anticancer drug should target a particular feature or a pathway of the tumour that does not exist or is significantly different in normal cells. The majority of anticancer drugs on the market are focused on DNA or protein targets that are involved in the proliferation of the tumour cells. However, even if the proliferation of cancer cells is completely inhibited or eliminated during such treatments, the remaining nonproliferating dormant (Aguirre-Ghiso, 2006) , senescent (Roninson, 2003) and resting stem cells (Sell, 2006) can reenter the cell cycle and cause tumour relapse after initial remission. Therefore, truly effective anticancer therapies should affect both proliferating and nonproliferating populations of tumour cells. However, the pathways targeted are unlikely to be completely unique to tumours, and inhibition of these pathways in nontumour cells may lead to toxicity and adverse effects in patients (Eastman & Perez, 2006) . In some cases the growth and survival of tumour cells depends on a pathway that, while being common to both kinds of cell, is not essential for the normal cells, as they possess an additional alternative/redundant pathway. This phenomenon is known as 'oncogene addiction' (Eastman & Perez, 2006; Weinstein & Joe, 2008) , and it can be exploited for selective and successful anticancer drug design. An example of oncogene addiction is the interplay between human coatomer protein complex I (COPI) subunits 1 and 2. Human COPI is a coat protein that is involved in autophagy and intracellular protein trafficking between the endoplasmic reticulum and the Golgi apparatus in the early secretory pathway (Beck et al., 2009; Razi et al., 2009; Bé thune et al., 2006; Lee et al., 2004) .
The COPI consists of a cytosolic seven-subunit protein complex, which reversibly associates with the non-clathrincoated vesicles of the Golgi and mediates transport from the endoplasmic reticulum (Waters et al., 1991) . The subunits forming COPI are organized into two subcomplexes: -COP, 0 -COP and "-COP comprise a heterotrimer, while -COP, -COP, -COP and -COP form a heterotetramer (Lowe & Kreis, 1995) . -COP (Cop) is an $20 kDa subunit of COP that is required for coated vesicle assembly and binding of coatomer to the Golgi membranes (Kuge et al., 1993) . Subsequently, -COP and -COP were both shown to exist in two distinct isoforms (Futatsumori et al., 2000) , and each isoform is present in the coatomer as a single copy. These findings resulted in the suggestion that there are several distinct COPI forms that are present in many or most mammalian cells (Wegmann et al., 2004; Blagitko et al., 1999) . These COPI isoforms were later shown to have different distributions and localizations within the Golgi apparatus (Moelleken et al., 2007) . The abundance of different COPI isoforms was reassessed and the relative ratio of 1/1, 1/2 and 2/1 was shown to be $10:3:5, with the majority of 1/2-COP localized within the early Golgi compartment. The authors have estimated the amount of the 2/2-COPI isoform to be <5% of the total. It has recently been shown that the Cop2 isoform (but not Cop1) is significantly down-regulated in the majority of tumour-cell lines and clinical samples of different cancer types (Shtutman et al., 2011) . This down-regulation makes the tumour cells dependent on Cop1. Interestingly, no oncogenic activities of overexpressed Cop1/2 have been reported both in vitro and in vivo. Knockdown of Cop1 was shown to be lethal to cancer cells, causing collapse of the Golgi apparatus, loss of autophagy and induced apoptosis, whereas normal cells were unaffected. Simultaneous knockdown of both Cop1/2 subunits caused similar effects in normal cells. Furthermore, tumour cells in which Cop1 was knocked down could be rescued by re-expression of Cop2, supporting the hypothesis that tumour-associated Cop2 silencing causes the 'addiction' of tumour cells to Cop1. These results also suggest that specific inhibition of Cop1 subunit insertion into the coatomer (ideally with no adverse effect on Cop2 assembly) represents a promising anticancer drug avenue. A structure of the Cop1 subunit is required to provide a basis for structurebased rational drug design. In 2009, Yu and coworkers reported a solution NMR structure of the Cop1 subunit (Yu et al., 2009 ), but no crystal structure of the Cop1 or the Cop2 subunit is yet available in the Protein Data Bank. In this article the cloning, recombinant expression and purification of both Cop1 and Cop2 are reported, as well as the highresolution crystal structure of Cop1.
Materials and methods

Cloning
A commercially available (Eurofins) plasmid (pEX-A2) containing a synthetic gene encoding N/C-terminally truncated human Cop1 (residues 7-150; UniProt ID P61923) was purchased and used for further subcloning into the Escherichia coli pETM-11 expression vector (Dü mmler et al., 2005) . The pETM-11 expression system is based on the T7 promoter, allowing the use of high-yield autoinduction medium (Studier, 2005) . A synthetic E. coli codon-optimized gene was used to increase the probability of successful soluble expression. The sequence encoding residues 7-150 of human Cop1 contained NcoI and HindIII restriction sites at the 5 0 and 3 0 ends, respectively. pEX-A2-Cop1 plasmid and pETM-11 vector were both digested with NcoI and HindIII restriction enzymes (Thermo Scientific) according to the manufacturer's recommendations and ligated by T4 DNA ligase (Thermo Scientific). The ligation mixture was incubated at 293 K for 10 min followed by heat inactivation at 338 K for 10 min according to the manufacturer's recommendations. The final construct contained a synthetic sequence encoding truncated Cop1 (7-150) with a His 6 tag, linker sequence and Tobacco etch virus (TEV) digestion site fused at the N-terminus (Table 1) .
Cloning of truncated human Cop2 (UniProt ID Q9P299) was performed similarly. The final Cop2 construct contained a synthetic sequence encoding truncated human Cop2 (40-183) with a His 6 tag, linker sequence and TEV digestion site fused to the N-terminus (Table 1) .
Expression and purification
E. coli BL21 (DE3) RIL competent cells transformed with the pETM-11-Cop1 expression plasmid were propagated in 0.5 l selective medium (ZYM5052 in the presence of 100 mg ml À1 kanamycin and 35 mg ml À1 chloramphenicol) overnight at 310 K according to the autoinduction protocol of Studier (2005) . At an OD 600 of 2.0, the temperature was decreased to 291 K. After overnight expression, the cells were harvested by centrifugation at 4000g for 30 min, resuspended in 30 ml wash buffer [50 mM Tris-HCl pH 8.0, 300 mM NaCl, 5%(v/v) glycerol, 3 mM -mercaptoethanol (BME), 20 mM imidazole] and lysed by sonication on ice for 6 min at 50% amplitude (Branson W250D). The lysate was clarified by centrifugation at 41 000g for 60 min. All steps were performed at 277 K and no protease-inhibitor cocktails were used. No protein degradation was observed during the purification.
The lysate containing soluble His 6 -tagged recombinant Cop1 was filtered with a 2 mm filter membrane (Whatman) and further incubated with 2 ml Ni-NTA agarose (Macherey Nagel) for 10 min at 277 K. The agarose was washed with 100 ml wash buffer in order to remove contaminations using a gravity-flow column (BioRad). After the washing step, the recombinant His 6 -tagged Cop1 bound to Ni-NTA agarose was mixed with 8 ml digestion buffer [50 mM Tris-HCl pH 8.0, 300 mM NaCl, 5%(v/v) glycerol, 5 mM BME, 2 mg recombinant TEV protease] and incubated at 277 K overnight in order research communications to perform on-column His 6 -tag digestion. After overnight digestion the flowthrough fraction containing digested nonHis 6 -tagged Cop1 was collected and subsequently concentrated to a volume of 1 ml using a centrifugal concentrator with a 5 kDa cutoff (Sartorius).
The digested Cop1 was further purified using a Superdex 75 16/60 size-exclusion column (GE Healthcare). The protein was purified in SEC buffer [20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 20 mM sodium citrate, 300 mM NaCl, 5%(v/v) glycerol, 3 mM BME] and eluted at a volume of $80 ml as a single peak. This peak was pooled and concentrated using a centrifugal concentrator with a 5 kDa cutoff (Sartorius) to 10 mg ml À1 for crystallization. The final protein concentration was determined based upon its theoretical absorbance at 280 nm. The protein purity was estimated to be better than 95% (not shown) as assessed by Coomassie Brilliant Blue-stained SDS-PAGE (Laemmli, 1970) . The final yield of Cop1 was in excess of 40 mg per litre of culture.
The expression and purification of human Cop2 was performed identically apart from the use of E. coli BL21 (DE3) Rosetta2 pLysS as the expression cell line. Similarly, the elution volume of Cop2 during size-exclusion purification was $80 ml. The final yield of Cop2 was comparable to that of Cop1.
Differential scanning fluorimetry
The buffer composition for the size-exclusion purification steps of Cop1 and Cop2 was chosen based upon a differential scanning fluorimetry (DSF; Thermofluor) assay (Ericsson et al., 2006; Nettleship et al., 2008) . SYPRO Orange fluorescent dye (Invitrogen) dissolved in 100% DMSO was added to the protein sample (concentrated to 2 mg ml À1 ) at 1:500 dilution. Each well of the 96-well plate PCR plate contained 5 ml protein-dye solution and 45 ml of the buffer component to be screened. A stability assay was performed using a CFX96 Real-Time PCR Detection System (Bio-Rad) at a temperature gradient from 293 to 368 K in steps of 0.5 K. The inflection points in graphs of relative fluorescence units (RFU) against temperature (i.e. melting temperature; T m ) were determined manually and used as an indicator of the sample thermal stability in the buffer component screened. Comparisons were made against control samples containing only protein/water. The optimal SEC buffer composition for both Cop1 and Cop2 was selected based on the components that showed a positive shift in the melting temperature and consisted of 20 mM HEPES pH 7.5, 20 mM sodium citrate, 300 mM NaCl, 5%(v/v) glycerol, 3 mM BME. The stabilization effect of the optimal SEC buffer on Cop1 compared with the wash buffer is shown in Fig. 1(a) .
In order to select Cop2/Cop1 candidate-binding partners from a small-molecule compound library (Professor Alexander Dö mling, Department of Drug Design, University of Groningen), further DSF-based experiments were performed. Candidate compounds were selected based on the positive shifts of the inflection point. The assay was performed similarly to the initial stability assay. Experiments were composed of 5 ml of the candidate compound (100 mM solubilized in DMSO) and 45 ml of the protein-dye mixture diluted in SEC buffer. Comparisons were made against a control sample containing only protein and DMSO and no compound. Based on these trials, 2-(3-hydroxy-4-methoxyphenyl)acetic acid was selected for further co-crystallization (Figs. 1c and 1e) . Table 1 Macromolecule-production information.
A synthetic gene encoding human Cop1 was subcloned into the pETM-11 expression vector using NcoI (CCATGG) and HindIII (AAGCTT) restriction sites (underlined). Cloning of Cop2 was performed similarly. The His 6 tag (bold) and TEV protease cleavage site (underlined) are also indicated. The beginning and ending numbers of the amino-acid sequences are shown as subscripts.
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Source 
Crystallization
Initial high-throughput crystallization screening (Gryphon robot, ARI) was performed in MRC2 96-well plates using the sitting-drop technique. Screening was performed against the PACT premier, JCSG plus (Molecular Dimensions) and Index (Hampton Research) sparse-matrix screens. Screening for the crystallization conditions for Cop1 without additives did not yield positive results. Co-crystallization screening was also performed using the compound selected from the smallmolecule library using DSF (Fig. 1c) . The sitting-drop experiments were performed using MRC2 96-well plates with 0.1 ml protein/compound solution (10 mg ml À1 /10 mM) mixed with 0.1 ml screen condition and stored at 289 K. Multiple Cop1 crystals appeared in various conditions containing 2-3 M sodium malonate, dl-malic acid or sodium citrate at pH 6.0 within a few days. Further optimization of the crystallization buffer was performed by varying the precipitant type and concentration using the hanging-drop technique. Drops of protein sample mixed with crystallization reagent in a 1:1 ratio were equilibrated against 500 ml reservoir solution at 295 K. The optimal conditions consisted of equal volumes (1.5 ml) of Cop1 sample at 14 mg ml À1 and 2.2 M dl-malic acid, 0.2 M sodium malonate pH 6.2 in the presence of 10 mM 2-(3-hydroxy-4-methoxyphenyl)acetic acid and 10%(v/v) DMSO (Table 2 ). Small rectangular-shaped thin plate-like crystals of Cop1 (Fig. 2) appeared within a few days and were subsequently flash-cooled in liquid nitrogen for further storage and shipment. No further cryoprotection was necessary owing to the high precipitant concentration in the crystal-growth buffer.
Crystallization trials of Cop2 were performed identically. However, no Cop2 crystals have yet been observed.
Data collection and processing
Cop1 crystals were shipped to the PETRA III synchrotron facility, Hamburg, Germany using a dry-shipping container (Taylor-Wharton), and a 1.6 Å resolution data set was collected at 100 K in a nitrogen stream on the P11 beamline. The crystal belonged to space group C121, with unit-cell parameters a = 109.4, b = 65.4, c = 37.3 Å , = 90.0, = 96.6, = 90.0 and diffracted to below 1.6 Å resolution. A data set consisting of 3600 frames was collected. After initial data processing performed automatically using pipelines based on the XDS software (Kabsch, 2010) , the data set was truncated to 1700 frames. No crystal twinning was detected. The datacollection statistics are shown in Table 3 .
The structure of human Cop1 was solved by molecular replacement using MOLREP (Vagin & Teplyakov, 2010) within the CCP4 package (Winn et al., 2011) . The solution NMR structure of human Cop1 (PDB entry 2hf6; Yu et al.,
2009
) was used as a search model, yielding a solution with two monomers in the asymmetric unit. The model was further optimized using manual rebuilding via Coot (Emsley & Cowtan, 2004) and was refined with REFMAC (Murshudov et al., 2011 ). All refinement steps were carried out with automatically generated local NCS restraints and TLS restraints calculated via the TLSMD web server (Painter & Merritt, 2006a,b) . The final 1.6 Å resolution model of human Cop1 consisted of two molecules in the asymmetric unit with an R factor of 0.21 and a free R factor of 0.25 (Table 4) , and was deposited in the PDB with accession code 5mc5.
Results and discussion
A truncated version of human Cop1 (residues 7-150) was cloned, recombinantly expressed and purified. The N-and Small (50-100 mm) diffraction-quality crystals of Cop1 grown in 2.2 M dl-malic acid, 0.2 M sodium malonate pH 6.2 in the presence of 10 mM 2-(3-hydroxy-4-methoxyphenyl)acetic acid. ) 17.9 † R meas is defined as P hkl fNðhklÞ=½NðhklÞ À 1g 1=2 P i jI i ðhklÞ À hIðhklÞij= P hkl P i I i ðhklÞ, where I i (hkl) is the ith intensity measurement of reflection hkl and hI(hkl)i is the average intensity from multiple observations. The free R factor was calculated using a randomly selected 5% of reflections omitted from the refinement. Table 2 Crystallization of Cop1.
The buffer composition of the protein solution was chosen based upon the results of the DSF stability assay (Fig. 1 Table 4 Structure solution and refinement. 2.92 † The free R factor was calculated using a randomly selected 5% of reflections omitted from the refinement.
C-terminal truncations were based on the results of Yu et al. (2009) , in which full-length Cop1 showed no secondary structure for the first ten amino acids of the N-terminus and self-proteolysis near the C-terminus. A shorter construct of Cop1 (residues 17-150) expressed insolubly (data not shown). Similarly, a truncated version of human Cop2 (residues 40-183) was cloned, expressed and purified, and the truncations were based on the high degree of homology between Cop1 and Cop2 (74.9% identity).
A differential scanning fluorimetry (DSF)-based screening of purified Cop1 and Cop2 was performed against a fragment library of small-molecule compounds. A potentially binding fragment [2-(3-hydroxy-4-methoxyphenyl)acetic acid] was selected based on the increased thermal stability of both Cop1 (ÁT m = 5.5 K) and Cop2 (ÁT m = 3 K) in the presence of this compound (Figs. 1c and 1e ). Co-crystallization trials of both proteins yielded diffraction-quality crystals of Cop1 in the presence of 2-(3-hydroxy-4-methoxyphenyl)acetic acid. Interestingly, no apo crystals of Cop1 were observed in the absence of the compound even after an extended time period, suggesting that the presence of the small molecule is essential for crystallization. Extensive crystallization trials of Cop2 were performed similarly in the presence and absence of the compound, but to date no Cop2 crystals have been observed. A 1.6 Å resolution X-ray data set from a Cop1 crystal grown in the presence of 2-(3-hydroxy-4-methoxyphenyl)-acetic acid was collected on the P11 beamline at PETRA III, DESY, Hamburg, and the structure of Cop1 with two molecules in the asymmetric unit and an R factor of 0.21 and an R free of 0.25 has been deposited in the PDB with accession code 5mc7.
Overall, the Cop1 monomer consists of five -sheets surrounded by five -helices (Fig. 3a) . A comparison of our crystal structure of human Cop1 with the solution NMR structure (Yu et al., 2009) indicates that the crystal structure and solution NMR structures are highly similar (Fig. 3b) , strongly suggesting that the crystal structure represents the solution form of free Cop1. Based on this comparison, we suggest that the N-terminal region of Cop1 shows no secondary structure. The inability to detect electron density for the first five N-terminal residues of the construct (residues 7-11) supports this hypothesis. A region between 1 and 3 (residues 52-58) shows a significant rearrangement (8.3 Å Figure 3 (a) Overall structure of human Cop1. (b) Superposition of the crystal structure of human Cop1 (pale green) and the solution NMR Cop1 structure (orange; PDB entry 2hf6; Yu et al., 2009) shows no significant differences except for the flexible loop between 1 and 3 (residues 52-58) and the region between 5 and 2 (residues 81-87). (c) A comparison between two superimposed molecules (pale green and blue) in the asymmetric unit of the crystal structure of human Cop1 shows significant differences in the flexible-loop region. The coordinates were superimposed using Coot (Emsley & Cowtan, 2004; Jomaa et al., 1999) . difference for Thr55 and 9.3 Å for Asp56), suggesting high flexibility of this loop. Comparison between the two molecules within our Cop1 structure shows similar behaviour of the flexible loop, with shifts of 5.4 Å for Thr55 and 6.9 Å for Asp56. Another loop region between 5 and 2 (residues 81-87) shows a 4.9 Å shift between both molecules in our Cop1 structure and the solution NMR structure of Yu and coworkers.
Further comparison with the electron-microscopy structure of the /-Cop complex (PDB entry 5a1u; Dodonova et al., 2015) suggests a rearrangement of the flexible loop (residues 52-58) upon binding to -Cop. This shift may indicate that Cop1 undergoes structural rearrangement during assembly into the COPI complex that can potentially be used in the design of small molecules (Fig. 4) . However, the low resolution of the EM structure strongly suggests that this hypothesis needs to be further assessed.
Despite the fact that Cop1 only crystallized in the presence of the potentially interacting compound 2-(3-hydroxy-4-methoxyphenyl)acetic acid, no unambiguous electron density for this compound was observed in the crystal structure. Further co-crystallization and biophysical experiments are under way in order to identify compounds that interact selectively with Cop1. The availability of the high-resolution crystal structure of Cop1 will aid in the search for hit compounds and further structure-based drug design.
